Analyze Publications Database

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma

Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther. February 2012;11(2):383-392.

Full Text – Open Access

Publication Date
February 2012

How Analyze was Used
“Image processing and analysis were carried out using commercially available software (AnalyzePC; AnalyzeDirect). Raw data were reformatted and object maps of desired regions of interest were outlined.”

Keywords
Angiogenesis Inhibitors/administration & dosage/pharmacology
Animals
Antigens/metabolism
Antigens, CD31/metabolism
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carcinoma, Renal Cell/drug therapy/metabolism/pathology
Cell Line, Tumor
Cell Proliferation/drug effects
Cells, Cultured
Human Umbilical Vein Endothelial Cells/drug effects/metabolism
Humans
Immunohistochemistry
Kidney Neoplasms/drug therapy/metabolism/pathology
Magnetic Resonance Imaging (MRI)
Mice
Mice, Inbred BALB C
Mice, Nude
Neovascularization, Pathologic/metabolism/pathology/prevention & control
Proteoglycans/metabolism
Sirolimus/administration & dosage/analogs & derivatives/pharmacology
Spheroids, Cellular/drug effects/metabolism
TOR Serine-Threonine Kinases/antagonists & inhibitors/metabolism
Tumor Burden/drug effects
Xanthones/administration & dosage/pharmacology
Xenograft Model Antitumor Assays/methods

Author Affiliation(s)
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, US. (LE, KL, PS, RP)

Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, US. (GA)

Department of Pharmacology and Therapeutics, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, US. (MS)

The Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore, MD, US. (PS, HH)

ID# 483

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,